Logo-bi
Original Research
Ysrafil Ysrafil* ORCID, Indwiani Astuti ORCID
BioImpacts. 2022;12(3): 195-202. doi: 10.34172/bi.2021.22119
PMCID: PMC9124874     PMID: 35677668     Scopus ID: 85132077892    
Chitosan nanoparticle antimiRNA-324-5p could inhibit ovarian cancer proliferation by reduce endogenous miRNA-324-5p to lead restoration of MEN1 and generates repression of GLI1 expression.
Editorial
Yalda Rahbar Saadat ORCID, Jaleh Barar* ORCID
BioImpacts. 2022;12(2): 87-88. doi: 10.34172/bi.2022.24253
PMCID: PMC8905586     PMID: 35411296     Scopus ID: 85127210127    
Jaleh Barar (PharmD, Ph.D.) is a Full Professor at the Faculty of Pharmacy, Tabriz University of Medical Sciences. Professor Barar is working on various aspects of pharmaceutical cell biology with particular emphasis on the development of novel drug delivery/targeting systems. Dr Barar is listed among top 1% of world scientists based on ESI ranking system.
Original Article
Fateme Arjmand ORCID, Samaneh Shojaei, Mitra Khalili, Hossein Dinmohammadi, Behzad Poopak, Samira Mohammadi-Yeganeh* ORCID, Yousef Mortazavi* ORCID
Bioimpacts. 2024;14(4): 28870. doi: 10.34172/bi.2023.28870
PMCID: PMC11298021     PMID: 39104620     Scopus ID: 85198951433    


As a peer-reviewed international open-access journal, BioImpacts publishes articles on basic and translational aspects of pharmaceutical and biomedical sciences. 
Acceptance rate: 24% 
Publication fee: Free of charge